You are here: Industry Insights > licensing

News List

Working Collaboratively: Using Co-operation to Boost Pipelines Suzanne Elvidge
September 26, 2024
As drugs, devices and other healthcare products become more innovative and complex, and as development costs increase, working collaboratively becomes more important.
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag americanpharmaceuticalreview
June 26, 2019
Shionogi announces the Company has concluded an agreement with Eddingpharm to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name in Japan: MULPLETA®).
Lilly and Avidity Biosciences enter into licensing and research collaboration biospectrumasia
April 25, 2019
Collaboration will pursue therapeutic targets focused on immunology and other indications
Eli Lilly inks deal with ImmuNext to jointly develop therapies for autoimmune diseases firstwordpharma
March 28, 2019
Eli Lilly and ImmuNext announced a collaboration to jointly study a preclinical novel target that could facilitate the development of new treatments for autoimmune disorders that regulate immune cell metabolism.
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries fiercepharma
November 14, 2018
AbbVie has had success with its new pan-genotypic hepatitis C drug Mavyret, generating blockbuster-level sales at the expense of competitors.
Lilly signs licensing and research deal with Dicerna Pharmaceuticals pharmaceutical-technology
October 31, 2018
Eli Lilly has entered a global licensing and research alliance with Dicerna Pharmaceuticals to identify, develop and commercialise potential therapies for cardio-metabolic conditions, neurodegeneration and pain.
Carrick bags ex-Onyx cancer drug, plans pivotal trials fiercebiotech
October 12, 2018
Carrick revealed details of the licensing agreement alongside news that it has appointed George Golumbeski as chairman.
Glenmark Announces Licensing Agreement with Seqirus americanpharmaceuticalreview
July 11, 2018
Glenmark Pharmaceuticals announced its subsidiary Glenmark Specialty has entered into an exclusive licensing agreement with Seqirus to commercialize Ryaltris in Australia and New Zealand.
Antibe signs distribution agreement with Acbel for ATB-346 drug pharmaceutical-technology
February 28, 2017
Antibe Therapeutics has signed a licensing and distribution agreement with Laboratoires Acbel for the drug ATB-346 in Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan.
Shuwen Biotech Receives EN ISO 13485 Certification b3cnewswire
January 16, 2017
Shuwen Biotech Co. Ltd., a China-based diagnostic company focused on licensing, developing and commercializing diagnostic kits and services for unmet clinical needs, announced that it has received EN ISO 13485 certification.